Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.87 |
| ▸ | VCP | P55072 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.87 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | PNP | P00491 | 5/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | EDNRA | P25101 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60629 | 1.00 | BLM (0.87) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL3663790 | 1.00 | BLM (0.87) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL3033 | 0.93 | BLM (1.00) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL2160505 | 0.93 | BLM (1.00) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL10481442 | 0.92 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL2433042 | 0.92 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL25915 | 0.92 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL11121521 | 0.92 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL11093368 | 0.92 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL10899902 | 0.92 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253611-B2 | Thymidine kinase diagnostic assay for gene therapy applications | Genvivo, Inc. (US) | 2022-02-22 | — | — | US | claimed |
| US-20250345409-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | GENVIVO INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12350327-B2 | Compositions and methods for therapeutic or vaccine delivery | Genvivo, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250115930-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | Genvivo, Inc. | 2025-04-10 | — | — | US | disclosed |
| US-12234475-B2 | Compositions and methods for therapeutic delivery | Genvivo, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240366746-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | Genvivo, Inc. | 2024-11-07 | — | — | US | disclosed |
| WO-2024226784-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | Genvivo, Inc. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4423288-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | GenVivo, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423287-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | GenVivo, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118556129-A | Compositions and methods for therapeutic agent delivery | 吉恩维沃公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023076177-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | Genvivo, Inc. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076180-A2 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | Genvivo, Inc. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4126867-A1 | THIOPURINE-BASED COMPOUND, COMPOSITION, METHOD OF PREPARATION AND APPLICATIONS | SeeCure Taiwan Co., Ltd. (TW) | 2023-02-08 | — | — | EP | disclosed |
| US-20220401581-A1 | THYMIDINE KINASE GENE | Genvivo, Inc. | 2022-12-22 | — | — | US | disclosed |
| CN-115298178-A | Thiopurine compound, composition, preparation method and application | 聚天生医股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022178840-A1 | THIOPURINE-BASED COMPOUND, COMPOSITION, METHOD OF PREPARATION AND APPLICATIONS | SEECURE TAIWAN CO. , LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
| US-11364307-B2 | Thymidine kinase gene | Genvivo, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022099209-A1 | BIO-FUNCTIONALIZATION OF WATER-SOLUBLE POLY(PHENYLENE ETHYNYLENE)S | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11253611-B2 | Thymidine kinase diagnostic assay for gene therapy applications | Genvivo, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11242314-B2 | Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride | WASHINGTON UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242314-B2 | Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride | STX18, GPR119, SLC5A1 | BLM 3654/4885MEN1 250/4885ALDH1A1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.